Complix Overview
- Year Founded
-
2008
- Status
-
Private
- Employees
-
11
- Latest Deal Type
-
2ndary - Private
- Investors
-
12
Complix General Information
Description
Operator of a biopharmaceutical company intended to target intractable or challenging disease targets. The company is developing a transformative pipeline of alpha body therapeutics primarily addressing intracellular disease targets that play an important role in cancer, autoimmunity, and viral diseases, enabling patients to overcome the limitations of conventional antibodies and small molecules by combining the specific potency of biologics with the cell-penetrating capacity and stability of small molecules.
Contact Information
Website
www.complix.comCorporate Office
- BioVille
- Agoralaan building A-bis
- 3590 Diepenbeek
- Belgium
Corporate Office
- BioVille
- Agoralaan building A-bis
- 3590 Diepenbeek
- Belgium
Complix Valuation & Funding
| Deal Type | Date | Amount | Raised to Date | Post-Val | Status | Stage |
|---|---|---|---|---|---|---|
| 14. Secondary Transaction - Private | 01-Feb-2025 | Completed | Pre-Clinical Trials | |||
| 13. Grant | 07-Oct-2020 | Completed | Pre-Clinical Trials | |||
| 12. Later Stage VC | 01-Jan-2020 | Completed | Pre-Clinical Trials | |||
| 11. Later Stage VC (Series D) | 05-Aug-2019 | Completed | Pre-Clinical Trials | |||
| 10. Secondary Transaction - Private | 01-Feb-2019 | Completed | Pre-Clinical Trials | |||
| 9. Grant | 14-Dec-2017 | Completed | Pre-Clinical Trials | |||
| 8. Later Stage VC (Series C) | 30-Jun-2017 | Completed | Pre-Clinical Trials | |||
| 7. Later Stage VC (Series B) | 10-Apr-2015 | Completed | Pre-Clinical Trials | |||
| 6. Later Stage VC (Series B) | 27-May-2014 | $5.14M | $18.7M | Completed | Pre-Clinical Trials | |
| 5. Later Stage VC (Series B) | 20-Aug-2013 | $4.35M | $13.6M | Completed | Pre-Clinical Trials |
Complix Cap Table
| Stock | # of Shares Authorized |
Par Value | Dividend Rate (%) | Original Issue Price |
Liquidation | Liquidation Pref. Multiple |
Conversion Price | % Owned |
|---|---|---|---|---|---|---|---|---|
| Series D | ||||||||
| Series C | ||||||||
| Series B | 15,934,290 | $0.69 | $0.69 | 1x | $0.69 | 9.77% | ||
| Series A | 11,323,198 | $0.69 | $0.69 | 1x | $0.69 | 6.94% |
Complix Comparisons
Industry
Financing
Details
Complix Competitors (81)
One of Complix’s 81 competitors is Zura Bio, a Formerly VC-backed company based in Henderson, NV.
| Company Name | Financing Status | Location | Employees | Total Raised | Last Financing Date/Type | Last Financing Amount |
|---|---|---|---|---|---|---|
| Zura Bio | Formerly VC-backed | Henderson, NV | ||||
| Agomab Therapeutics | Formerly VC-backed | Antwerp, Belgium | ||||
| Prothena | Corporation | Dublin, Ireland | ||||
| CimCure | Venture Capital-Backed | Amsterdam, Netherlands | ||||
| Vera Therapeutics | Formerly VC-backed | Brisbane, CA |
Complix Patents
Complix Recent Patent Activity
| Publication ID | Patent Title | Status | First Filing Date | Technology (CPC) | Citations |
|---|---|---|---|---|---|
| WO-2023203127-A1 | Alphabody-based degrader molecules | Inactive | 20-Apr-2022 | ||
| WO-2023170173-A1 | Polypeptides capable of inhibiting sars-cov-2 viruses | Inactive | 08-Mar-2022 | ||
| EP-4036117-A1 | Mcl-1 binding alphabodies and uses thereof | Inactive | 27-Jan-2021 | ||
| EP-4284833-A1 | Mcl-1 binding alphabodies and uses thereof | Inactive | 27-Jan-2021 | ||
| US-20240317807-A1 | Mcl-1 binding alphabodies and uses thereof | Inactive | 27-Jan-2021 | C07K14/00 |
Complix Signals
Complix Investors (12)
| Investor Name | Investor Type | Holding | Investor Since | Participating Rounds |
|---|---|---|---|---|
| Vlaanderen verbeelding werkt | Limited Partner | |||
| VLAIO | Limited Partner | Minority | ||
| Baekeland Fonds II | Corporation | Minority | ||
| Gimv | PE/Buyout | Minority | ||
| PMV (Belgium) | Asset Manager | Minority |
Complix FAQs
-
When was Complix founded?
Complix was founded in 2008.
-
Where is Complix headquartered?
Complix is headquartered in Diepenbeek, Belgium.
-
What is the size of Complix?
Complix has 11 total employees.
-
What industry is Complix in?
Complix’s primary industry is Drug Discovery.
-
Is Complix a private or public company?
Complix is a Private company.
-
What is Complix’s current revenue?
The current revenue for Complix is .
-
How much funding has Complix raised over time?
Complix has raised $31.4M.
-
Who are Complix’s investors?
Vlaanderen verbeelding werkt, VLAIO, Baekeland Fonds II, Gimv, and PMV (Belgium) are 5 of 12 investors who have invested in Complix.
-
Who are Complix’s competitors?
Zura Bio, Agomab Therapeutics, Prothena, CimCure, and Vera Therapeutics are some of the 81 competitors of Complix.
Data Transparency
-
Meet our data hygiene team
Discover how our experts ensure you’re getting the most accurate financial data in the industry.
Read more -
How PitchBook sources data
Our data operations team has logged over 3.5 million hours researching, organizing, and integrating the information you need most.
Discover our process